Divis Laboratories Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/1hsow63wdhy8f5cqwsai1dgc.pdf

Key Takeaways


Supply Chain & Cost Environment

Nilima Prasad Divi: "Right now, we can say it is difficult, but it is not something that we are completely worried about."

Generic Business & Pricing


Custom Synthesis & Dedicated Capacity

Dr. Kiran S. Divi: "The cycle is typically when we do an innovative product, we completely depend on the customer's timeline because we file in their CMC. We do not have control on when the product will be launched. It can be wishful thinking if you want it in 6 months or 1 year, it can take 2 years."

Peptide Business

Dr. Kiran S. Divi: "We have several 3,000-liter SPPS, which by far in India nobody has. We are quite strong and committed towards this segment, and we are targeting to be one of the largest global players in the world."

Contrast Media


Margins & Profitability

Nilima Prasad Divi: "I mean with the change in scenarios, I would say it's difficult to project, but we would say it would remain stable. And we would -- like it's also with the situation we are currently in, we wouldn't want to throw a figure on that."

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growthDouble-digit growth; "that's the projection the company would like to assume it would achieve"FY27
Margin stabilityMargins expected to "remain stable" vs current levels; no figure givenFY27
Capex run-rateCapex expected to be constant vs current year, unless a major new CS project or new project arisesFY27
Dedicated CS commercializationThree projects through validation, supplied to customers; commercialization depends on customer regulatory approvalsHopeful by 2027, earlier or later
Freight cost pressureExpected to continue in the near term; incorporated into planningComing quarters
Inventory buildIncrease likely to be seen from Q1 as company secures and stores materialQ1 FY27 onward

Key Metrics

MetricQ4 FY26
Consolidated total income₹2,986 cr
Profit before tax₹963 cr, vs ₹864 cr in Q4 FY25
Profit after tax₹751 cr
Forex gain₹90 cr
Full-year consolidated total income₹11,067 cr, vs ₹9,712 cr in FY25
Full-year profit before tax₹3,388 cr, after ₹74 cr Labour Codes impact; vs ₹2,916 cr in FY25
Full-year profit after tax₹2,568 cr, vs ₹2,191 cr in FY25
Full-year forex gain₹211 cr, vs ₹48 cr in FY25
Full-year material consumption38.8% of sales revenue, vs 39.8% in FY25
Full-year constant currency growth6.82%
Full-year product mix (Generics : CS)45% : 55%
Full-year nutraceuticals revenue₹946 cr, vs ₹781 cr in FY25
Full-year export contribution89% of total sales revenue; Europe and US 74% of export revenue
Full-year assets capitalized₹1,544 cr, of which ~₹800 cr in Q4
Capital work in progress (Mar 31, 2026)₹2,113 cr
Cash and cash equivalents (Mar 31, 2026)₹3,414 cr
Receivables (Mar 31, 2026)₹2,984 cr
Inventories (Mar 31, 2026)₹3,954 cr
Full-year capex~₹2,500 cr, ~23-24% of sales; vs ₹1,400 cr in FY25
Full-year operating margin (excl. other income)~32-32.5% (per an analyst's math)
Labour Codes one-time impact (FY26)₹74 cr, fully provided as exceptional item